Published in Drug Week, May 4th, 2007
Results of the studies presented at the AACR meeting demonstrated a potent, dose-dependent inhibition of tumor growth following the administration of ENMD-1420 (previously CC-5079) in two distinct preclinical models of metastatic lung and colorectal carcinoma. At maximally tolerated doses, tumor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.